Newsroom

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 1/19/2026 Issue ¦ Yorkshire Water Services Finance Plc GBP 125,000,000 1.46% RPI Linked due 01 Aug 2056     ISIN Number ¦ XS0275222114 ISIN Reference ¦ 27522211 Issue Nomin GBP ¦ 125000000 Period ¦ 8/1/2025 to 2/1/2026   Payment Date 2/2/2026 Number of Days ¦ 184 Rate ¦ 2.967275   Denomination GBP ¦ 50000   ¦ 125000000   ¦       Amount Payable per Denomination ¦ 741.82   ¦ 1854546.75   ¦       Bank...

WALL, N.J.--(BUSINESS WIRE)--The board of directors (the “Board”) of New Jersey Resources Corporation (NYSE: NJR) unanimously declared a quarterly dividend on its common stock of $0.475 per share. The dividend will be payable on April 1, 2026, to shareowners of record as of March 11, 2026. NJR has paid quarterly dividends continuously since its inception in 1952, and has raised the dividend every year for the last 30 years. About New Jersey Resources New Jersey Resources (NYSE: NJR) is a Fortun...

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces its financial calendar for the 2026 fiscal year as well as the resumption of its participation in investor conferences. Events Date 2025 Annual Results April 9, 2026 Q1 2026 Sales April 16, 2026 2026 Annual General Meeting June 4, 2026 Q2 2026 Sales July 21, 2026 20...

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth : ALMKT) (la « Société ») inventeur de Cellvizio®, la plateforme multidisciplinaire d'endomicroscopie confocale laser par minisonde et par aiguille (p/nCLE), annonce son calendrier financier pour l’exercice 2026 ainsi que la reprise de sa participation aux conférences investisseurs. Événements Date Résultats annuels 2025 9 avril 2026 Chiffre d’affaires T1 2026 16 avril 2026 Assemblée générale ordinaire 202...

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Applicati...

DUBLIN--(BUSINESS WIRE)--The "Floating Hotels Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Floating Hotels Market, valued at USD 4.83 billion in 2025, is projected to grow to USD 5.19 billion in 2026 and further expand to USD 8.03 billion by 2032, reflecting a steady CAGR of 7.50%. Positioned at the intersection of maritime engineering and hospitality innovation, floating hotels offer a unique proposition by integrating advanced vessel architectur...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., an emerging leader in advanced solutions for atrial fibrillation, is proud to announce the publication of the PULSAR clinical trial results in the Journal of the American College of Cardiology (JACC). This landmark study evaluated the Globe® Pulsed Field System by Kardium for the treatment of paroxysmal atrial fibrillation (PAF). The multicenter pivotal trial demonstrated that the Globe System achieved durable pulmonary vein isolation...

SAN FRANCISCO--(BUSINESS WIRE)--BIOMAKERS raised an additional $8M to scale its AI-native precision oncology platform, accelerating drug and diagnostic development....

SEATTLE--(BUSINESS WIRE)--Lighthouse today announced the launch of LighthouseIQ, a next-generation intelligence platform and AI application suite....

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tr...